DRG Market Assessment reports

Chronic heart failure (CHF) is a long-term condition primarily managed by angiotensin-converting enzyme (ACE) inhibitors, oral beta blockers, or oral diuretics. The addition of a second- or third-…

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico…

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India,…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic heart failure (CHF) patient populations, covering 171…

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute heart failure (AHF) patient populations, covering 171…

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF…

Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this…

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…

Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…